Who is sponsoring NCT01414920?

NCT01414920 is sponsored by Takeda.

What condition does NCT01414920 study?

NCT01414920 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01414920?

Interventions: Placebo, TAK-875, TAK-875, Sitagliptin, TAK-875 and Sitagliptin, TAK-875 and Sitagliptin.

What is the status of NCT01414920?

NCT01414920 is currently COMPLETED.

Last reviewed 2016-03-04 · How we verify

A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus

NCT01414920 Phase 2 COMPLETED

The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).

Details

Lead sponsor	Takeda
Phase	Phase 2
Status	COMPLETED
Enrolment	368
Start date	2011-08
Completion	2012-08

Conditions

Diabetes Mellitus, Type 2

Interventions

Placebo
TAK-875
TAK-875
Sitagliptin
TAK-875 and Sitagliptin
TAK-875 and Sitagliptin

Primary outcomes

Change from Baseline in Glycosylated Hemoglobin (HbA1c) — Baseline and Week 12.
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 relative to baseline.

Countries

United States